Novo Nordisk A/S
CNBC Daily Open: Even a Supreme Court ruling might not spell the end of tariffs
The US Supreme Court in Washington, DC, US, on Monday, Oct. 6, 2025. Graeme Sloan | Bloomberg | Getty Images The U.S. Supreme Court on Wednesday heard a case on the Trump administration’s “reciprocal” tariffs, and both liberal and conservative judges appeared skeptical of the legal basis of those tariffs. Following the hearing, traders on […]
Read More
Healthy Returns: What to know about Pfizer and Novo Nordisk’s bidding war over obesity biotech Metsera
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, with both pharmaceutical giants raising their bids for the startup as of Monday. […]
Read More
Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount
A box of Ozempic sits on a table in North Tyneside, Britain, Oct. 31, 2023. Lee Smith | Reuters Danish pharmaceutical giant Novo Nordisk said Wednesday it is trimming its growth expectations for its leading obesity and diabetes treatments as competition intensifies and pricing pressures mount in the weight loss market. Net profit for the […]
Read More
Europe to open lower as markets question tech valuations; Novo Nordisk earnings ahead
European stocks are expected to open lower, mirroring global declines as concerns grow over sky-high tech valuations. Source
Read More
Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Metsera on Tuesday said Novo Nordisk‘s new […]
Read More
Pfizer tops estimates, raises profit guidance even as sales fall
Smith Collection | Archive Photos | Getty Images Pfizer on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit guidance, as cost cuts helped to outweigh declining sales for the period. The pharmaceutical giant now expects its full-year adjusted profit to come in between $3 and $3.15 per share, up […]
Read More
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., Sept. 30, 2025. Mike Blake | Reuters Pfizer on Monday said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker’s attempt to outbid Pfizer to acquire the obesity biotech is […]
Read More
November trading, Berkshire’s cash hoard, Big Tech’s ad revenue and more in Morning Squawk
A trader works on the floor of the New York Stock Exchange on Oct. 30, 2025 in New York. Angela Weiss | AFP | Getty Images This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Here are five key things investors need to know to start the trading day: 1. November […]
Read More
Where the blockbuster weight loss drug market stands today — and what’s coming next
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters The appetite for blockbuster weight loss and diabetes drugs is far from satisfied. From fresh competition to new uses, the market is quickly vaulting into a new stage of […]
Read More
Global week ahead: Is Novo Nordisk past ‘peak uncertainty’?
At one point, it was Europe’s most valuable company. Now, as Danish pharmaceutical group Novo Nordisk prepares to publish its third-quarter earnings on Wednesday, the picture looks very different. Jonathan Raa | Nurphoto | Getty Images CNBC’s Charlotte Reed will travel to Copenhagen to speak with the company’s new CEO Mark Doustdar, a 30-year veteran […]
Read More